9MW 3811
Alternative Names: 9MW-3811Latest Information Update: 19 Nov 2025
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 11 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Hypertrophic scars; Idiopathic pulmonary fibrosis; Pulmonary fibrosis; Solid tumours
Most Recent Events
- 11 Nov 2025 National Medical Products Administration (NMPA) approves clinical trial application for 9MW 3811 for phase-II trial in Hypertrophic scars
- 11 Nov 2025 Pharmacodynamics data from preclinical trial in Hypertrophic scars released by Mabwell Therapeutics
- 11 Nov 2025 Mabwell Therapeutics plans a phase-II trial for Hypertrophic scars in China at the end of 2025 (Parenteral)